Form 4: Anixa Biosciences Director Increases Stake Through Open Market Purchases

Anixa Biosciences director Lewis H. Titterton Jr. acquired 3,000 shares of common stock through open market purchases on January 23rd and 24th, 2025.

Summary

• Lewis H. Titterton Jr., a director at Anixa Biosciences, purchased 2,000 shares of common stock on January 23, 2025, at a price of $2.91 per share.
• He then purchased an additional 1,000 shares on January 24, 2025, at a price of $3.00 per share.
• Following these transactions, Mr. Titterton's total direct holdings in Anixa Biosciences increased to 933,334 shares.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the director's open market purchases, which are generally seen as a sign of confidence in the company. However, it's a single transaction and not a major event.

Positives

• The director's open market purchases indicate confidence in the company's future prospects.
• Increased insider ownership can be viewed positively by the market.

Industry Context

Insider trading activity is closely monitored by investors as it can provide insights into management's view of the company's prospects. Open market purchases by directors are generally seen as a positive sign.

Comparison to Industry Standards

• Comparing this to other similar biotech companies, insider purchases are common, but the size and frequency can vary significantly.
• For example, directors at companies like Xencor or Iovance Biotherapeutics also make open market purchases, but the amounts and timing are specific to each company's situation and stock price.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive signal, potentially increasing confidence in the company.
• The purchase could have a minor positive impact on the stock price.

Key Dates

Keywords

Anixa Biosciences, insider trading, Form 4, stock purchase, director, Lewis H. Titterton Jr., share ownership